Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442970 in moderate to severe hidradenitis suppurativa
NCT05849922Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of brivekimig in hidradenitis suppurativa (HS), sponsored by Sanofi. Started Jun 2023; status: completed.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05849922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849922.